Pentasa rectal suspension 1 g/100 ml bottle 100 ml No. 7

Pentasa rectal suspension is indicated for ulcerative proctosigmoiditis and left-sided colitis.

Composition

Active ingredient: mesalazine;

100 ml of suspension contains 1 g of mesalazine;

Excipients: sodium edetate (Trilon B), sodium metabisulfite (E 223), sodium acetate, trihydrate; concentrated hydrochloric acid; purified water.

Contraindication

Hypersensitivity to salicylates, the active substance or any of the excipients. Severe liver and/or kidney dysfunction.

Method of application

It is recommended to empty the bowel before using an enema.

Application features

Pregnant women

Can be used only when the expected benefit to the mother outweighs the potential risk to the fetus.

Drivers

Does not affect.

Overdose

There is only limited clinical experience with overdose of Pentasa, which does not indicate renal or hepatic toxicity. There is no specific antidote, treatment should be symptomatic and supportive. There have been reports of patients taking daily doses of up to 8 g for a month without any side effects.

Side effects

The most common adverse reactions observed during clinical studies were diarrhea, nausea, abdominal pain, headache, vomiting, and rash.

Hypersensitivity reactions and drug fever are sometimes observed.

After rectal administration, local reactions such as itching, rectal discomfort and urge to defecate are possible.

Interaction

Concomitant treatment with Pentasa and azathioprine, 6-mercaptopurine or thioguanine in studies led to an increased incidence of myelosuppressive effects, probably there is an interaction between these agents. The mechanism of this interaction has not been fully elucidated. It is recommended to regularly monitor the level of leukocytes and adjust the doses of thiopurines accordingly.

Storage conditions

Store at a temperature of 15 °C - 25 °C in the original packaging.

Keep out of reach of children.

Shelf life - 3 years.